Investing

Corbus Pharmaceuticals : CRBP

CRBP

Stock Data

$10.29

$0.41 (3.79%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Corbus Pharmaceuticals Holdings Inc is a pioneering biopharmaceutical company focused on creating innovative treatments for serious illnesses. With a robust pipeline that includes CRB-701, a targeted therapy for cancer, and lenabasum, a novel treatment for inflammation and fibrosis, Corbus is at the forefront of medical research. The company also explores treatments for obesity and related metabolic diseases with CRB-913. Based in Norwood, Massachusetts, and founded in 2009, Corbus is committed to advancing healthcare through groundbreaking research and partnerships, such as its collaboration with Jenrin Discovery, LLC.

All Corbus Pharmaceuticals Articles

7 Articles

Trey Thoelcke | Oct 6, 2024 at 9:45 AM EDT

An Airline, Biotechs, and More See Huge Insider Buying

Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs,…

Trey Thoelcke | Sep 29, 2024 at 9:15 AM EDT

Check Out Last Week’s Big Insider Buying: Biotechs, Energy, and More

A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of…

Rich Duprey | Sep 8, 2024 at 7:43 AM EDT

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled…

Trey Thoelcke | Mar 17, 2024 at 9:10 AM EDT

Buffett Can’t Get Enough of This Stock, Plus Other Insider Buying

Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying of communication and aviation stocks in…

Trey Thoelcke | Feb 12, 2024 at 8:53 AM EST

Another Huge Buffett Purchase Highlights Recent Insider Buying

Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to…

Trey Thoelcke | Feb 5, 2024 at 12:09 PM EST

Insider Buying at These Biotechs Is Huge

As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at…

Douglas A. McIntyre | Sep 5, 2020 at 6:31 AM EDT

These Are The Robinhood Stocks With The Highest Analyst Rating

Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in…